Search Results
Your search for ,kEY matches 7151 pages
Showing 51 - 100CLL Linked to Increased Skin Cancer Risk and Mortality
In a nationwide population–based cohort study reported in JAMA Dermatology, Blomberg Drejøe et al evaluated the long-term risk of skin cancer and related outcomes among patients with chronic lymphocytic leukemia (CLL). By leveraging comprehensive Danish health registries, the investigators aimed to ...
Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center
International leader in blood cancer and stem cell research Ulrich Steidl, MD, PhD, has been named Director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Vice President of Cancer Medicine at Montefiore Einstein. He has acted as Interim Director of MECCC, which is a National...
Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Besse et al, the final report from the phase I/II ARROW trial supports the efficacy of the RET inhibitor pralsetinib in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC). The initial reports from the trial supported U.S. ...
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
Long-term follow-up of the oral selective RET inhibitor pralsetinib in patients with advanced non–small cell lung cancer (NSCLC) and a RET fusion confirms its efficacy and safety, according to final findings from the phase I/II ARROW trial published in the Journal of Clinical Oncology. “Before...
IMPT vs IMRT in Oropharyngeal Cancer
As reported in The Lancet by Thomson et al, the UK phase III TORPEdO trial has shown similar outcomes with intensity-modulated proton therapy (IMPT) vs intensity-modulated radiation therapy (IMRT) in patients with locally advanced oropharyngeal squamous cell carcinoma. Study Details In the...
Metastatic Papillary Renal Cancer: Final Results With Savolitinib and Durvalumab
As reported in the Journal of Clinical Oncology by Jackson-Spence et al, final results of the phase II CALYPSO study indicated better overall survival and other outcomes with savolitinib and durvalumab among patients with metastatic papillary renal cancer who have MET-driven disease. Study...
Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases
In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed high intracranial activity and progression-free survival in patients with triple-negative breast...
Low Food Access May Lead to More Complications After Breast Reconstruction
Researchers have identified a possible link between living in an area of lower food access and postoperative outcomes and complications after breast reconstruction, according to study results published in Plastic and Reconstructive Surgery. "Our findings suggest that access to healthy foods and...
Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
In a phase I trial reported in The New England Journal of Medicine, Park et al identified the toxicity profile and preliminary antitumor activity of setidegrasib, a first-in-class KRAS G12D–targeted protein degrader, in patients with previously treated advanced non–small cell lung cancer (NSCLC) or ...
Ablative Radiotherapy May Improve Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
A new study published by Jaoude et al in Clinical Cancer Research demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma. The retrospective study was led ...
Fullerene Cream vs Trolamine Cream in Reducing Acute Radiation Dermatitis From Radiation Therapy for Head and Neck Cancer
In a single-center phase II trial conducted in China and reported in the Journal of Clinical Oncology, Liu et al found that fullerene cream was superior to trolamine cream in reducing the risk of acute radiation dermatitis (ARD) in patients receiving definitive or adjuvant radiation therapy (RT)...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors
Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring and care, according to findings published in Communications Medicine. The study authors noted that...
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for melanoma detection. The study was undertaken to address a critical gap in the literature: while prior...
Low-Risk Endometrial Cancer: Does a Lack of Adjuvant Therapy Affect Survival?
In a study reported in a research letter in JAMA Oncology, Matsuo et al found that survival without adjuvant therapy in women with low-risk endometrial cancer was poorer among those with isolated tumor cells (ITCs) vs no lymph node metastasis in regional lymph nodes. Study Details The cohort...
Financial Hardship and Late-Stage Cancer Diagnosis
In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with organized screening programs and those detectable via physical examination. Study Details The...
Agent Orange Exposure Linked to MDS Risk and Progression
In a recent study published in Blood Advances, Sekeres et al examined whether exposure to Agent Orange, a dioxin-contaminated herbicide used during the Vietnam War, is associated with the development and clinical characteristics of myelodysplastic syndromes (MDS). Given the established links...
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
One-time low-dose computed tomography (CT) screening for lung cancer in a non–risk-based Chinese population led to a significant reduction in lung cancer mortality, according to the results of a prospective, nonrandomized, controlled study presented at the European Lung Cancer Congress 2026...
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
An interpretable machine-learning framework, called PRE-Screen-HCC, may predict risk levels for developing hepatocellular carcinoma (HCC) more accurately than publicly available risk scores, according to findings from a large population-based multicentric study published in Cancer Discovery. “Our...
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-line setting, according to findings presented during the first European Society for Medical...
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
In a French phase II trial (GCO-001-NIPINEC) reported in the Journal of Clinical Oncology, Walter et al found that nivolumab plus ipilimumab showed some activity in patients with advanced gastroenteropancreatic (GEP) or lung large-cell neuroendocrine carcinoma (NEC) after failure of platinum-based...
Risk of Subsequent Cancer in Solid Organ Transplant Recipients With Pretransplant Cancer History
In a study reported in JAMA Oncology, Tao et al found that U.S. solid organ transplant (SOT) recipients with a history of pretransplant cancer were at increased risk of subsequent cancer. Study Details The cohort study used linked data from the U.S. Scientific Registry of Transplant Recipients and ...
Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
As reported in The New England Journal of Medicine by Langley et al, a UK phase III trial (PATCH/STAMPEDE-1) has shown noninferiority in metastasis-free survival with the use of transdermal estradiol (tE2) patches vs luteinizing hormone–releasing hormone (LHRH) agonist treatment in men with locally ...
Molecular Test Doubles Detection of Bile Duct Cancer
When patients develop a narrowing or blockage in the bile ducts, physicians must determine whether the cause is cancer or a benign condition. The location of these blockages adds challenges to the diagnosis, and this uncertainty can delay treatment decisions for patients in the event they have this ...
Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment
In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting most from the addition of PD-1 inhibition to chemoradiotherapy (CRT) in locoregionally advanced...
Adjuvant Atezolizumab and mFOLFOX6 in Stage III Mismatch Repair–Deficient Colon Cancer
As reported in The New England Journal of Medicine by Sinicrope et al, the phase III ATOMIC trial has shown that the addition of adjuvant atezolizumab to mFOLFOX6 (modified fluorouracil, oxaliplatin, and leucovorin) improved disease-free survival in patients with resected stage III mismatch...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Licitra et al, the phase III LEAP-010 trial showed an improved objective response rate and progression-free survival—but not overall survival—with the addition of first-line lenvatinib to pembrolizumab in patients with recurrent or metastatic head...
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
AI Model for Predicting Oncotype DX 21-Gene Recurrence Score
As reported in The Lancet Oncology, Shamai et al have developed an artifical intelligence (AI) model based on digital histopathology slide images and clinical features to predict the Oncotype DX 21-gene recurrence score (RS) in patients with hormone receptor–positive, HER2-negative invasive breast...
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identified patient datasets from participating cancer centers, while maintaining patient security,...
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
In an interim analysis of a Chinese phase II/III trial (ZSAB) reported in The New England Journal of Medicine, Shi et al found that a neoadjuvant GOLP regimen (gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor [toripalimab]) improved event-free survival vs no neoadjuvant treatment in...
Using AI to Differentiate Primary Lung Squamous Cell Carcinomas From Metastases
A multipronged artificial intelligence (AI)–assisted approach integrated into routine molecular profiling identified 3.1% of cases submitted as lung squamous cell carcinoma as metastases from other origins, revealing a meaningful rate of misdiagnosis in this patient population, according to a...
Gedatolisib-Based Regimens in HR-Positive, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer
In a phase III trial (VIKTORIA-1) reported in the Journal of Clinical Oncology, Hurvitz et al found that gedatolisib and fulvestrant both with and without palbociclib improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative, PIK3CA wild-type...
Hyperplasia and the Link Between Obesity and Cancer
Research has uncovered that an increase in organ size from hyperplasia due to increased weight may increase the risk for several obesity-related cancers, according to findings published in Cancer Research. “People have long been told that obesity increases cancer risk, but they are rarely told...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings
POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monoclonal plasma cell dyscrasia, and skin changes. Clinical manifestations are thought to result from...
SIOG 2025: Celebrating 25 Years of Leadership in Geriatric Oncology
The 25th Annual Conference of the International Society of Geriatric Oncology (SIOG) convened in Ghent, Belgium, from November 20 to 22, 2025, marking a quarter-century of international collaboration dedicated to improving cancer care for older adults. Held under the theme “Bridging Research and...
AI Model Classifies Challenging Thymic Epithelial Tumors
A deep learning model can diagnose thymic epithelial tumors with high sensitivity for thymic carcinoma detection, according to findings published in Annals of Oncology. The researchers suggested that the tool could be used to improve diagnostic consistency and support decision-making in settings...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
The Thymus Plays a Part in Adult Cancer Risk and Treatment Response, Research Reveals
Two papers published in Nature reveal long-disregarded functions of the thymus in adulthood, showing that the overall health of the organ impacts aging and risks for cardiovascular disease and cancer, as well as affecting response to immunotherapy in patients with cancer. “The thymus has been...
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
In a systematic review and meta-analysis reported in The Lancet Oncology, Varey et al found that patients undergoing sentinel node biopsy (SLNB) for melanoma had reduced risk of melanoma-specific mortality and disease recurrence vs those who did not undergo SLNB. Study Details The analysis included ...
Hypofractionated Locoregional RT in Early Breast Cancer
As reported in The Lancet by Rivera et al, 5-year results of a French phase III trial (UNICANCER HypoG-01) showed noninferiority of hypofractionated locoregional radiotherapy (RT) vs standard 5-week RT in reducing risk of postsurgery lymphedema in patients with early breast cancer. Study Details In ...
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response...
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges. This annual survey on...
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with...
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
A new analysis suggests that prostate cancer screening may compare favorably with screening for breast cancer in terms of identifying significant cancers, reducing mortality, and avoiding unnecessary harms, according to findings presented at the 2026 Annual Congress of the European Association of...
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients with locally advanced/metastatic urothelial carcinoma. The results from the randomized phase III...
